SG11202112539XA - A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator - Google Patents
A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulatorInfo
- Publication number
- SG11202112539XA SG11202112539XA SG11202112539XA SG11202112539XA SG11202112539XA SG 11202112539X A SG11202112539X A SG 11202112539XA SG 11202112539X A SG11202112539X A SG 11202112539XA SG 11202112539X A SG11202112539X A SG 11202112539XA SG 11202112539X A SG11202112539X A SG 11202112539XA
- Authority
- SG
- Singapore
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183641 | 2019-07-01 | ||
| PCT/EP2020/068181 WO2021001286A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112539XA true SG11202112539XA (en) | 2021-12-30 |
Family
ID=67137842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112539XA SG11202112539XA (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220251064A1 (en) |
| EP (1) | EP3993795A1 (en) |
| JP (1) | JP2022537994A (en) |
| KR (1) | KR20220029687A (en) |
| CN (1) | CN114008032B (en) |
| AR (1) | AR119317A1 (en) |
| AU (1) | AU2020299705A1 (en) |
| BR (1) | BR112021022379A2 (en) |
| CA (1) | CA3139622A1 (en) |
| CL (1) | CL2021002949A1 (en) |
| CO (1) | CO2021017740A2 (en) |
| EC (1) | ECSP22007557A (en) |
| IL (1) | IL289317A (en) |
| MA (1) | MA56445A (en) |
| MX (1) | MX2021015872A (en) |
| PE (1) | PE20220373A1 (en) |
| SA (1) | SA521431274B1 (en) |
| SG (1) | SG11202112539XA (en) |
| TW (1) | TWI842923B (en) |
| WO (1) | WO2021001286A1 (en) |
| ZA (1) | ZA202109194B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3211578A1 (en) * | 2021-03-09 | 2022-09-15 | Kevin Michael BIGLAN | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008223145A1 (en) | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine H3 receptor |
| KR101284796B1 (en) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | method for light emitting device with can package and the light emitting device |
| JO3316B1 (en) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | 3,4-dihydroisoquinolin-2(1h)-yl compounds |
| CN107001278B (en) | 2014-10-08 | 2020-11-24 | Ucb生物制药私人有限公司 | Tetrahydroisoquinoline derivatives |
| US10370355B2 (en) * | 2016-04-13 | 2019-08-06 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| WO2018167113A1 (en) * | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| TWI725408B (en) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | Dopamine d1 receptor positive allosteric modulators |
-
2020
- 2020-06-29 US US17/621,871 patent/US20220251064A1/en active Pending
- 2020-06-29 CA CA3139622A patent/CA3139622A1/en active Pending
- 2020-06-29 AU AU2020299705A patent/AU2020299705A1/en active Pending
- 2020-06-29 EP EP20735361.6A patent/EP3993795A1/en active Pending
- 2020-06-29 MX MX2021015872A patent/MX2021015872A/en unknown
- 2020-06-29 WO PCT/EP2020/068181 patent/WO2021001286A1/en active Application Filing
- 2020-06-29 MA MA056445A patent/MA56445A/en unknown
- 2020-06-29 SG SG11202112539XA patent/SG11202112539XA/en unknown
- 2020-06-29 BR BR112021022379A patent/BR112021022379A2/en unknown
- 2020-06-29 JP JP2021575050A patent/JP2022537994A/en active Pending
- 2020-06-29 KR KR1020227002603A patent/KR20220029687A/en unknown
- 2020-06-29 PE PE2021002217A patent/PE20220373A1/en unknown
- 2020-06-29 CN CN202080043673.9A patent/CN114008032B/en active Active
- 2020-06-30 AR ARP200101852A patent/AR119317A1/en unknown
- 2020-06-30 TW TW109122034A patent/TWI842923B/en active
-
2021
- 2021-11-08 CL CL2021002949A patent/CL2021002949A1/en unknown
- 2021-11-17 ZA ZA2021/09194A patent/ZA202109194B/en unknown
- 2021-12-23 IL IL289317A patent/IL289317A/en unknown
- 2021-12-23 CO CONC2021/0017740A patent/CO2021017740A2/en unknown
- 2021-12-30 SA SA521431274A patent/SA521431274B1/en unknown
-
2022
- 2022-01-31 EC ECSENADI20227557A patent/ECSP22007557A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA521431274B1 (en) | 2024-01-09 |
| PE20220373A1 (en) | 2022-03-16 |
| ZA202109194B (en) | 2023-11-29 |
| KR20220029687A (en) | 2022-03-08 |
| MX2021015872A (en) | 2022-02-03 |
| WO2021001286A1 (en) | 2021-01-07 |
| ECSP22007557A (en) | 2022-02-25 |
| EP3993795A1 (en) | 2022-05-11 |
| BR112021022379A2 (en) | 2022-03-08 |
| JP2022537994A (en) | 2022-08-31 |
| CN114008032B (en) | 2023-11-10 |
| TW202115009A (en) | 2021-04-16 |
| AU2020299705A1 (en) | 2021-12-09 |
| CN114008032A (en) | 2022-02-01 |
| CL2021002949A1 (en) | 2022-07-15 |
| CA3139622A1 (en) | 2021-01-07 |
| CO2021017740A2 (en) | 2022-01-17 |
| US20220251064A1 (en) | 2022-08-11 |
| MA56445A (en) | 2022-05-11 |
| IL289317A (en) | 2022-02-01 |
| TWI842923B (en) | 2024-05-21 |
| AR119317A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201911804D0 (en) | Crypotgraphy using a crypotgraphy state | |
| IL289314A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| GB2590523B (en) | A connector | |
| GB201813470D0 (en) | A drumstick | |
| ZA202103581B (en) | Novel aminophosphinic derivatives as aminopeptidase a inhibitors | |
| IL289317A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| IL277811A (en) | A substituted oxopyridine derivative | |
| GB202015090D0 (en) | Corner-protection structure for a case | |
| GB2585886B (en) | A signal generator | |
| GB201908704D0 (en) | A plug | |
| GB2587811B (en) | A Cabinet | |
| GB201918974D0 (en) | Gpr52 modulator compounds | |
| GB201918992D0 (en) | GPR52 modulator compounds | |
| GB201916298D0 (en) | GPR52 modulator compounds | |
| GB201903335D0 (en) | A sunlounger | |
| ZAA201801446S (en) | A capsule | |
| ZAF201801447S (en) | A capsule | |
| GB2572955B (en) | A clock | |
| GB2584451B (en) | A ballast distributor | |
| PT3883865T (en) | Seal for a single serve capsule | |
| AU2019901737A0 (en) | A plug | |
| GB201918274D0 (en) | A composition | |
| GB201919216D0 (en) | Tetrahydrobenzo-quinoline sulfonamides derivative compounds | |
| AU2019900735A0 (en) | A plug | |
| IL280130A (en) | Pharmaceutical compositions with a cdc7 inhibitor |